Ovarian carcinoma remains a major therapeutic challenge due to its tendency to develop resistance after initial response to chemotherapy. In this work, a collaboration between iBET, AbbVie and IPOLFG, we developed ovarian carcinoma patient-derived explant (OvC-PDE) cultures that retained architecture and cell type heterogeneity of the original tumour. This patient-derived model have potential applications in the study of drug response and resistance mechanisms and in the development of innovative precision medicine approaches.
Ovarian carcinoma remains a major therapeutic challenge due to its tendency to develop resistance after initial response to chemotherapy. In this work, a collaboration between iBET, AbbVie and IPOLFG, we developed ovarian carcinoma patient-derived explant (OvC-PDE) cultures that retained architecture and cell type heterogeneity of the original tumour. This patient-derived model have potential applications in the study of drug response and resistance mechanisms and in the development of innovative precision medicine approaches.
